{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:34:03Z","timestamp":1793036043282,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jaad.2013.04.031","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T13:00:36Z","timestamp":1368536436000},"page":"393-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1016","volume":"69","author":[{"given":"Derrick J.","family":"Stobaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli D.","family":"Ehrenpreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.04.031_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2133.1993.tb11849.x","article-title":"Isotretinoin for acne vulgaris\u201310 years later: a safe and successful treatment","volume":"129","author":"Layton","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.04.031_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2133.1994.tb08524.x","article-title":"Long-term safety of isotretinoin as a treatment for acne vulgaris","volume":"131","author":"Goulden","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.04.031_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1572-0241.2006.00632.x","article-title":"Possible association between isotretinoin and inflammatory bowel disease","volume":"101","author":"Reddy","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib4","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/ajg.2009.417","article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","volume":"104","author":"Bernstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1542\/peds.2004-2687","article-title":"Vaccine adverse event reporting system reporting source: a possible source of bias in longitudinal studies","volume":"117","author":"Goodman","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2013.04.031_bib6","unstructured":"Schluterman N, Smith SW. Lawyer reporting creates false data mining signals in FDA\u2019s adverse event reporting system. Poster session presented at: Drug Information Association 47th Annual Meeting; June 20, 2011; Chicago, IL."},{"key":"10.1016\/j.jaad.2013.04.031_bib7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ajg.2012.300","article-title":"The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting and prescription drug lawsuits","volume":"108","author":"Ehrenpreis","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib8","unstructured":"Food and Drug Administration. Adverse event reporting system\u00a0data files. Available from: URL:http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082193.htm. Accessed March 25, 2012."},{"key":"10.1016\/j.jaad.2013.04.031_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1468-3083.2008.03031.x","article-title":"Psoriasis associated with ulcerative colitis and Crohn\u2019s disease","volume":"23","author":"Cohen","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.04.031_bib10","unstructured":"McCarrell v Hoffmann LaRoche Inc. ATL-L-1951-03-MT Atlantic County (NJ Super Ct Law Div 2010)."},{"key":"10.1016\/j.jaad.2013.04.031_bib11","unstructured":"McCarrell v Hoffmann LaRoche Inc. Memorandum of decision on motion, ATL-L-1951-03-MT Counties of Atlantic and Cape May (NJ Super Ct Law Div 2008)."},{"key":"10.1016\/j.jaad.2013.04.031_bib12","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/ajg.2010.124","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","volume":"105","author":"Crockett","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2013.1344","article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","volume":"149","author":"Etminan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2013.04.031_bib14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/jid.2012.387","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","volume":"133","author":"Alhusayen","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.04.031_bib15","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/ibd.21654","article-title":"Pediatric inflammatory bowel disease: increasing incidence, decreasing surgery rate, and compromised nutritional status: a prospective population-based cohort study 2007-2009","volume":"17","author":"Jakobsen","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2013.04.031_bib16","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/ajg.2011.304","article-title":"Association between the use of antibiotics and new diagnoses of Crohn\u2019s disease and ulcerative colitis","volume":"106","author":"Shaw","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib17","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","volume":"105","author":"Margolis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib18","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/ajg.2011.308","article-title":"Bugs and drugs: insights into the pathogenesis of inflammatory bowel disease","volume":"106","author":"Nguyen","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib19","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/ajg.2010.398","article-title":"Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease","volume":"105","author":"Shaw","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2013.04.031_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.04.031_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1525-1497.2003.20130.x","article-title":"Adverse drug event monitoring at the Food and Drug Administration","volume":"18","author":"Ahmad","year":"2003","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jaad.2013.04.031_bib22","unstructured":"US Food and Drug Administration. Orphan drug act. Available from:\u00a0URL: http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/OrphanDrugAct\/default.htm. Accessed July 6, 2012."},{"key":"10.1016\/j.jaad.2013.04.031_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2133.1999.02662.x","article-title":"The psychological and emotional impact of acne and the effect of treatment with isotretinoin","volume":"140","author":"Kellett","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.04.031_bib24","doi-asserted-by":"crossref","unstructured":"Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol doi: 10.1111\/j.1440-0960.2012.00947.x. Published online September 26, 2012.","DOI":"10.1111\/j.1440-0960.2012.00947.x"},{"key":"10.1016\/j.jaad.2013.04.031_bib25","unstructured":"Food and Drug Administration. Adverse event reporting system (FAERS) (formerly AERS). Available from: URL:http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm. Accessed February 8, 2013"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213004234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213004234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:28:14Z","timestamp":1759271294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213004234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0190962213004234"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.04.031","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}